Business

Experimental Lung-Cancer Drug Fails to Impress Investors

Updated 2026-06-01 12:20 UTC 1 source Negative

A study found that an experimental lung-cancer drug, ivonescimab, reduced the risk of death by 34% compared with another drug. However, investors were not impressed, suggesting skepticism about its commercial potential.

Coverage timeline — 1 article

MarketWatch

An experimental lung-cancer drug could replace Keytruda one day. But investors aren’t wowed.

The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug

2026-06-01 12:06 UTC